# Robert W. Baird

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/robert-w-baird
Canonical HTML page: https://getbiobrief.com/entity/robert-w-baird

## Timeline

- **2026-09-06**: Wall Street Zen rating actions — Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
- **2026-08-24**: Deutsche Bank downgrades argenx — Deutsche Bank cut argenx from buy to hold.
- **2026-08-18**: Truist raises argenx target — Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
- **2026-08-17**: Piper Sandler raises argenx target — Piper Sandler boosted its argenx target from $1,075.00 to $1,215.00 with an overweight rating.
- **2026-08-05**: Tenaya Q2 miss — Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
- **2026-07-28**: Weiss Ratings upgrades Tenaya — Weiss Ratings moved Tenaya from sell (e+) to sell (d-), still within sell territory.
- **2026-07-27**: Baird raises argenx target — Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
- **2026-07-21**: argenx Q2 beat — argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
- **2026-07-02**: BofA lifts argenx target — Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.

## Recent coverage (3 stories)

### Tenaya $0.66 Stock vs $4 Consensus Target: Biotech Risk Signal
2026-09-09 08:13:24 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Full story: https://getbiobrief.com/story/tenaya-0-66-vs-4-target-biotech-risk

### ARE Q2 Revenue $662.78M: What Biotech Tenants Should Expect from FY’26 Guidance
2026-08-12 00:14:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Full story: https://getbiobrief.com/story/alexandria-biotech-tenant-implications-fy26

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.